NewsRx

Search our medical news database

Toronto Western Hospital

Ondansetron treatment doesn't significantly reduce fatigue

Published in Mental Health Business Week, July 23rd, 2005

In a recent clinical trial, ondansetron treatment failed to significantly reduce fatigue in patients with primary biliary cirrhosis (PBC).

"Fatigue is common" in PBC patients, hepatologists in Canada noted. "Altered central serotonergic neurotransmission may be involved in its pathogenesis."

In a "multicenter, randomized, double-blind, placebo-controlled, crossover trial," J.J. Theal and colleagues at Toronto Western Hospital "evaluated the efficacy of ondansetron, a selective 5-HT3 receptor subtype antagonist, for treating fatigue in PBC."

"A crossover design was chosen, allowing subjects to serve as their own...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Mental Health Business Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook